INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Iovance Biotherapeutics Inc. to Contact Law Firm

Core Insights - Iovance Biotherapeutics, Inc. is facing potential shareholder litigation due to undisclosed operational issues affecting its T cell immunotherapy product, Amtagvi [1] - The company reported a significant decline in quarterly product revenue and drastically reduced its full-year revenue guidance for 2025 [2] - Following the financial results announcement, Iovance's stock price experienced a dramatic drop of approximately 44.8% in one day [3] Financial Performance - Iovance's total product revenue for Q1 2025 was $49.3 million, down from $73.7 million in the previous quarter, indicating a decline of about 33% [2] - The full fiscal year 2025 revenue guidance was revised from a range of $450 million - $475 million to $250 million - $300 million, representing a reduction of over 40% at the midpoint [2] Stock Market Reaction - On May 8, 2025, Iovance's stock closed at $3.17 per share, but fell to $1.75 per share on May 9, 2025, marking a decline of about 44.8% [3]